Loading…
Terumo Corporation has secured exclusive global development and commercialization rights to Virtue sirolimus-eluting balloon (SEB) from Orchestra BioMed, with an upfront payment of $30 million and an equity commitment of $5 million.
“Virtue SEB is the first and only non-coated drug-eluting angioplasty balloon that delivers a proprietary bioabsorbable, sustained-release formulation of sirolimus.”medicalbuyer.co.in
Summarized from public sources; check the original articles before acting on it.